Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MaxCyte, Inc. - Common Stock
(NQ:
MXCT
)
1.300
+0.050 (+4.00%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MaxCyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 04, 2023
Via
Benzinga
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
October 04, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
September 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Recap: MaxCyte Q1 Earnings
↗
May 10, 2023
Via
Benzinga
Looking Into MaxCyte's Return On Capital Employed
↗
March 16, 2023
Via
Benzinga
MaxCyte's Earnings: A Preview
↗
March 14, 2023
Via
Benzinga
MaxCyte Earnings Perspective: Return On Capital Employed
↗
December 14, 2022
Via
Benzinga
MaxCyte to Participate in Baird Global Healthcare Conference
September 05, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
August 09, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
August 01, 2023
Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
July 13, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
July 10, 2023
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies.
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
July 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Upcoming Investor Conferences
June 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
May 11, 2023
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.
Via
Benzinga
Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
May 11, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Sonos, Inc. (NASDAQ: SONO) shares dipped 25.2% to $15.82 in pre-market...
Via
Benzinga
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 10, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
May 04, 2023
Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases
From
MaxCyte, Inc
Via
GlobeNewswire
7 Small-Cap Biotech Stocks with Massive Potential
↗
April 27, 2023
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical.
Via
InvestorPlace
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
April 12, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
↗
March 31, 2023
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...
Via
Benzinga
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
March 27, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For March 15, 2023
↗
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
March 08, 2023
MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
March 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023
↗
February 22, 2023
For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards.
Via
InvestorPlace
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
February 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
January 03, 2023
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies
From
MaxCyte, Inc
Via
GlobeNewswire
7 Hot Stocks to Book Profits In Before 2023
↗
December 19, 2022
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
